论文部分内容阅读
目的探讨厄贝沙坦与辛伐他汀联合治疗糖尿病肾病的临床效果。方法 93例早期糖尿病肾病患者,随机分为观察组(47例)和对照组(46例)。两组患者在医师指导下给予糖尿病饮食、适当运动、降血糖药物等一般治疗,对照组患者同时给予厄贝沙坦治疗,观察组患者在对照组治疗基础上给予辛伐他汀治疗。测定两组患者治疗前后的尿蛋白排泄率、血中总胆固醇、甘油三酯、低密度脂蛋白水平;观察两组患者治疗过程中不良反应情况。结果观察组治疗后的尿蛋白排泄率、总胆固醇、甘油三酯、低密度脂蛋白水平与对照组比较,差异有统计学意义(P<0.05)。两组均未发生严重不良反应。结论厄贝沙坦与辛伐他汀联合治疗糖尿病肾病有助于延缓肾损害进展,临床效果显著。
Objective To investigate the clinical effect of irbesartan and simvastatin in the treatment of diabetic nephropathy. Methods 93 patients with early diabetic nephropathy were randomly divided into observation group (n = 47) and control group (n = 46). Two groups of patients under the guidance of the physician to give the diabetic diet, appropriate exercise, hypoglycemic drugs and other general treatment, the control group of patients given irbesartan treatment, observation group patients in the control group on the basis of simvastatin treatment. The urinary protein excretion rate, total cholesterol, triglyceride and low density lipoprotein in the two groups were measured before and after treatment. The adverse reactions in the two groups were observed. Results After treatment, urinary protein excretion rate, total cholesterol, triglyceride and low density lipoprotein levels in the observation group were significantly different from those in the control group (P <0.05). No serious adverse reactions occurred in both groups. Conclusion Irbesartan and simvastatin combined treatment of diabetic nephropathy can delay the progression of renal damage, the clinical effect is remarkable.